NYSE - Nasdaq Real Time Price USD

Eli Lilly and Company (LLY)

770.00

-1.12

(-0.15%)

At close: May 17 at 4:00 PM EDT

771.62

+1.62

(+0.21%)

After hours: May 17 at 7:58 PM EDT

Top Research Reports for Microsoft, Eli Lilly & Costco

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Eli Lilly and Company (LLY) and Costco Wholesale Corporation (COST), as well a micro-cap stock Koss Corporation (KOSS).

Zacks 18 hours ago

LLY
-0.15%
COST

MSFT
Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control

Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.

Zacks 22 hours ago

LLY
-0.15%
LGNZZ

ANIP
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates

Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.

Zacks 22 hours ago

BAYRY

LLY
-0.15%
NVO
-0.86%
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly

Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.

Zacks 23 hours ago

VKTX

NVO
-0.86%
ROG.SW
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks yesterday

LLY
-0.15%
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk

Could Amgen be the next stock to soar due to a GLP-1 drug?

Motley Fool yesterday

AMGN
-0.71%
LLY
-0.15%
NVO
-0.86%
Eli Lilly’s efsitora alfa shows promise in Phase III T2D trials

Once-weekly insulin efsitora alfa offered non-inferior A1C reduction in the QWINT-2 and QWINT-4 trials.

Clinical Trials Arena yesterday

LLY
-0.15%
Zacks Investment Ideas feature highlights: Apple, Eli Lilly and Crocs

Apple, Eli Lilly and Crocs have been highlighted in this Investment Ideas article.

Zacks yesterday

LLY
-0.15%
^GSPC

CROX
3 Stocks to Buy Following Positive Earnings Results

All three of these companies saw buyers step up post-earnings, reflecting the positivity of their results.

Zacks yesterday

^GSPC

LLY
-0.15%
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance

Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.

Zacks yesterday

LLY
-0.15%
NVO
-0.86%
Roche’s New Weight-Loss Data Shows Lilly Isn’t Unbeatable in Obesity

The results, from a small trial of a drug called CT-388, hint that Roche could be a serious player in the weight-loss market in coming years.

Barrons.com yesterday

ROG.SW

LLY
-0.15%
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data

Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.

Zacks 2 days ago

ROG.SW

LLY
-0.15%
NVO
-0.86%
Dow Jones Futures Rise On Cisco, Walmart After Market Rally Hits Highs, Nvidia Breaks Out

Futures rose on Cisco and Walmart. On Wednesday, the Dow, S&P 500 and Nasdaq hit record highs, with Nvidia leading new buys.

Investor's Business Daily 2 days ago

NVDA

COMP

^GSPC
Lilly’s once-weekly insulin matches daily shots in late-stage tests

The results, which showed Lilly’s drug was as effective at controlling blood sugar as standard injections, come as Novo Nordisk seeks approval for a competing once-weekly insulin.

BioPharma Dive 2 days ago

LLY
-0.15%
NVO
-0.86%
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial

Roche Holding said its weight-loss drug candidate achieved positive results in an early-stage trial, giving the company a boost in its bid to catch up to Novo Nordisk and Eli Lilly in a class of medicines that has shaken up everything from pharma to snack companies.

The Wall Street Journal 2 days ago

RHHBF

RHHBY

RHHVF
These 2 No-Brainer Growth Stocks Are Breaking New Ground

The future keeps getting brighter for these companies.

Motley Fool 2 days ago

REGN

LLY
-0.15%
UPDATE 2-Lilly's weekly insulin as effective as daily doses in studies

Eli Lilly said on Thursday its once-weekly insulin injection, efsitora, showed blood sugar reduction that was consistent with commonly used daily insulins across two studies in patients with type 2 diabetes. Lilly and Novo Nordisk are both developing weekly injections for long-acting insulins that could reduce the treatment burden for patients with diabetes. Novo's weekly injection, insulin icodec, has been recommended for approval in Europe and is under regulatory review in the United States.

Reuters 2 days ago

LLY
-0.15%
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections. In the treat-to-target clinical trials, efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally.

PR Newswire 2 days ago

LLY
-0.15%
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector

Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.

Zacks 2 days ago

BIIB
+0.23%
LLY
-0.15%
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound

Eli Lilly And Co (NYSE:LLY) has reportedly reached a settlement agreement with a medi spa that sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, which contains tirzepatide. As part of the deal, Totality Medispa will pay Lilly a monetary payment and cease using Lilly’s branding to promote its products. In addition to the financial settlement, Totality Medispa is required to take corrective actions, including ensuring that any compounded tirzepatid

Benzinga 2 days ago

LLY
-0.15%
NVO
-0.86%

Performance Overview

Return	LLY	S&P 500
YTD	+32.55%	+11.18%
1-Year	+77.66%	+29.04%
3-Year	+305.73%	+27.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eli Lilly and Company (LLY)

Top Research Reports for Microsoft, Eli Lilly & Costco

Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control

Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates

4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk

Eli Lilly’s efsitora alfa shows promise in Phase III T2D trials

Zacks Investment Ideas feature highlights: Apple, Eli Lilly and Crocs

3 Stocks to Buy Following Positive Earnings Results

3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance

Roche’s New Weight-Loss Data Shows Lilly Isn’t Unbeatable in Obesity

Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data

Dow Jones Futures Rise On Cisco, Walmart After Market Rally Hits Highs, Nvidia Breaks Out

Lilly’s once-weekly insulin matches daily shots in late-stage tests

Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial

These 2 No-Brainer Growth Stocks Are Breaking New Ground

UPDATE 2-Lilly's weekly insulin as effective as daily doses in studies

With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin

Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector

Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound

Performance Overview